Abbott Laboratories (ABT): Price and Financial Metrics


Abbott Laboratories (ABT): $100.68

-0.39 (-0.39%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ABT POWR Grades

  • ABT scores best on the Stability dimension, with a Stability rank ahead of 88.61% of US stocks.
  • ABT's strongest trending metric is Growth; it's been moving down over the last 178 days.
  • ABT ranks lowest in Momentum; there it ranks in the 29th percentile.

ABT Stock Summary

  • ABT has a market capitalization of $183,983,146,200 -- more than approximately 99.2% of US stocks.
  • ABBOTT LABORATORIES's stock had its IPO on January 1, 1986, making it an older stock than 93.26% of US equities in our set.
  • The volatility of ABBOTT LABORATORIES's share price is greater than that of just 21.81% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to ABT, based on their financial statements, market capitalization, and price volatility, are DHR, TMO, DIS, VZ, and TMUS.
  • Visit ABT's SEC page to see the company's official filings. To visit the company's web site, go to www.abbott.com.

ABT Valuation Summary

  • In comparison to the median Healthcare stock, ABT's EV/EBIT ratio is 80.68% higher, now standing at 18.7.
  • Over the past 243 months, ABT's price/sales ratio has gone up 0.7.

Below are key valuation metrics over time for ABT.

Stock Date P/S P/B P/E EV/EBIT
ABT 2022-09-09 4.2 5.2 22.2 18.7
ABT 2022-09-08 4.1 5.1 21.9 18.5
ABT 2022-09-07 4.0 5.0 21.4 18.1
ABT 2022-09-06 3.9 4.9 21.0 17.7
ABT 2022-09-02 3.9 4.9 21.0 17.7
ABT 2022-09-01 4.0 5.0 21.5 18.1

ABT Growth Metrics

    The 3 year cash and equivalents growth rate now stands at 153.97%.
  • Its year over year cash and equivalents growth rate is now at -4.71%.
  • Its 4 year net income to common stockholders growth rate is now at 161.43%.
Over the past 33 months, ABT's revenue has gone up $14,193,000,000.

The table below shows ABT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-06-30 45,548 10,243 8,554
2022-03-31 44,514 9,961 7,725
2021-12-31 43,075 10,533 7,071
2021-09-30 42,308 11,264 7,244
2021-06-30 40,233 10,629 6,376
2021-03-31 37,338 9,823 5,724

ABT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABT has a Quality Grade of B, ranking ahead of 77.76% of graded US stocks.
  • ABT's asset turnover comes in at 0.559 -- ranking 70th of 680 Pharmaceutical Products stocks.
  • DVAX, RARE, and CORT are the stocks whose asset turnover ratios are most correlated with ABT.

The table below shows ABT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.559 0.557 0.230
2021-03-31 0.527 0.568 0.205
2020-12-31 0.499 0.566 0.166
2020-09-30 0.473 0.567 0.135
2020-06-30 0.462 0.576 0.128
2020-03-31 0.473 0.584 0.147

ABT Price Target

For more insight on analysts targets of ABT, see our ABT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $132.05 Average Broker Recommendation 1.48 (Moderate Buy)

ABT Stock Price Chart Interactive Chart >

Price chart for ABT

ABT Price/Volume Stats

Current price $100.68 52-week high $142.60
Prev. close $101.07 52-week low $98.81
Day low $98.81 Volume 6,214,500
Day high $100.89 Avg. volume 5,452,975
50-day MA $107.07 Dividend yield 1.87%
200-day MA $116.93 Market Cap 176.31B

Abbott Laboratories (ABT) Company Bio


Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013. (Source:Wikipedia)


ABT Latest News Stream


Event/Time News Detail
Loading, please wait...

ABT Latest Social Stream


Loading social stream, please wait...

View Full ABT Social Stream

Latest ABT News From Around the Web

Below are the latest news stories about ABBOTT LABORATORIES that investors may wish to consider to help them evaluate ABT as an investment opportunity.

DexCom: Great Products, Stock Is Too Expensive

Introduction

DexCom (DXCM) has risen sharply in recent years until the beginning of this year. The stock has entered a bear market. This is probably mainly due to the Fed's strict policy to contain inflation. Interest rates are rising sharply, correcting the prices of expensive growth stocks. DexCom is also a growth stock whose share price has declined.

Chart
Data by Yannick Frey on Seeking Alpha | September 21, 2022

10 Best Defensive Stocks to Buy According to Ray Dalio

In this article, we will look at the 10 best defensive stocks to buy according to Ray Dalio. If you want to explore similar stocks, you can also take a look at 5 Best Defensive Stocks to Buy According to Ray Dalio. Ray Dalio is a billionaire investor and hedge fund manager of Bridgewater Associates, […]

Yahoo | September 21, 2022

Quant Billionaire Jim Simons Loves These 10 Defensive Stocks

In this article, we discuss 10 defensive stocks that quant billionaire Jim Simons loves. If you want to read about some more stocks in the Simons portfolio, go directly to Quant Billionaire Jim Simons Loves These 5 Defensive Stocks. James Simons, the founder of New York-based Renaissance Technologies, manages an equity portfolio worth more than […]

Yahoo | September 21, 2022

FDA Concludes Oversight Shortcomings After Infant Formula Internal Review

The FDA concluded an internal review of agency actions related to the U.S. infant formula supply. The agency released a 10-page report, which is the result of information collected from more than 40 interviews with more than 60 FDA staff and leadership directly involved with the events that transpired. The review found that numerous shortcomings hampered the agency’s response to the U.S. infant formula supply problems this year. The FDA said a “confluence of systemic vulnerabilities” helped expl

Yahoo | September 21, 2022

Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Yahoo | September 21, 2022

Read More 'ABT' Stories Here

ABT Price Returns

1-mo -1.20%
3-mo -7.29%
6-mo -15.52%
1-year -17.76%
3-year 27.65%
5-year 106.86%
YTD -27.61%
2021 30.53%
2020 28.04%
2019 22.08%
2018 29.06%
2017 52.03%

ABT Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABT Dividend History

Continue Researching ABT

Here are a few links from around the web to help you further your research on Abbott Laboratories's stock as an investment opportunity:

Abbott Laboratories (ABT) Stock Price | Nasdaq
Abbott Laboratories (ABT) Stock Quote, History and News - Yahoo Finance
Abbott Laboratories (ABT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4772 seconds.